Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NEW-AGE

Financiado

A next generation platform for catalysing pre clinical development of drugs agai...

A next generation platform for catalysing pre clinical development of drugs against Alzheimer s and other degenerative diseases of old age Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditi... ver más

31/07/2018

UNIVDUN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-07-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

2 Participantes

UNIVDUN

149.96K€ | Lider

BODEGAS ESCUDERO

303.76K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2017-01-26
Fecha Fin: 2018-07-31

Líder del proyecto

UNIVERSITY OF DUNDEE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine. Developing new therapies to slow, halt, or reverse these pathologies is regarded as a key element in addressing this global health priority. No such therapies have been successfully developed to date. A major unsolved challenge faced by drug discovery organisations is that for most degenerative conditions, there are no prognostic markers that can be used to predict whether a candidate therapy is likely to improve clinical outcome. Our solution to this problem exploits the fact that the pathogenesis and progression of all degenerative diseases is associated with oxidative stress. Oxidative stress thus makes an excellent potential prognostic biomarker, but it has been difficult to measure in vivo. Now, under the REDOX ERC Advanced Investigator Award, we have developed a portfolio of next-generation mouse models in which oxidative stress can be monitored at single-cell resolution across all organs. Moreover, the measurements can also be performed non-invasively and in real-time. We believe that these mice provides a new platform with unprecedented utility that can be used by drug-discovery organisations to accelerate, reduce the costs, and increase the predictive power of their pre-clinical pipelines for degenerative conditions. To support commercial exploitation of these models, we will: a) Show that our oxidative stress biomarkers are elevated in mouse models for two degenerative conditions, Alzheimer’s and Hutchinson-Gilford Progeria Syndrome. b) Demonstrate that the biomarker signals are reduced in mice administered therapies believed to be disease-modifying.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores